UK COVID-19 trial finds no benefit of gout drug in hospitalized adults

A large British trial has halted enrolments to test gout drug colchicine as a potential treatment for patients hospitalized with COVID-19 after a sub-study of the trial found that the medication did not have any effect on the patients.

An independent panel suggested pausing recruitment of volunteers in the colchicine arm of the trial based on a preliminary analysis, scientists involved in UK's RECOVERY study said. The study is the world's largest trial of treatments for hospitalized COVID-19 adults.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)